en · de · es
sermorelin-notes.peptides1126.com › News › Bremelanotide Naming And Background — Field Notes

Bremelanotide Naming And Background — Field Notes

By Editorial Desk · published 2025-12-27 · last reviewed 2026-02-04 · News

The short version of certificate of analysis fits in a sentence. The long version — which is the one that helps — is below.

This page was last updated on 2026-02-04 and is reviewed periodically as new material appears.

Bremelanotide Naming and Background

Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.

Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.

Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.

Receptor Pharmacology and Study Measures

Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.

After subcutaneous administration, plasma concentrations rise within roughly thirty minutes and the elimination half-life is short, on the order of two to three hours. Reported physiological responses include transient increases in blood pressure and nausea, which tended to diminish with repeated dosing in trial settings. Because the peptide clears quickly, effects are not expected to persist long after a dose. Absorption from non-injected routes is poorly characterised, and nasal delivery produced variable plasma levels in older work.

Pt-141 at a glance

PropertyValueNotes
Molecular formulaC50H68N14O10Cyclic heptapeptide core
Molecular weight1025.2 g/molCalculated for the free base
CAS registry number189691-06-3Free base; the acetate salt has a separate entry
Solubility classWater-solubleFreely soluble in aqueous media near neutral pH
Typical storage2 to 8 °CProtect from light; avoid repeated freeze-thaw cycles

Bremelanotide Identity and Background

Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.

The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.

Related pages on this site

Storage Stability and Analytical Methods

Identity and purity are usually established with reversed-phase high-performance liquid chromatography combined with mass spectrometry. A gradient of water and acetonitrile containing trifluoroacetic acid is a common mobile phase, and ultraviolet detection near 214 nanometres responds to the peptide backbone. Mass spectrometry confirms the expected molecular mass and helps reveal truncation or oxidation products. Purity is reported as a peak-area percentage, a figure that depends on the wavelength and gradient used, so values from different laboratories are not always directly comparable. Peptide mapping and amino acid analysis provide additional confirmation when required.

Regulatory status varies by jurisdiction, where approved prescription products, compounded preparations and research-grade material are treated as distinct categories with different documentation requirements. Suppliers of research material commonly issue a certificate of analysis listing purity, identity and sometimes endotoxin content. Independent verification by a third-party laboratory is often recommended because self-reported figures are difficult to check. Literature discussions usually state the source, purity and storage conditions of the material used, since these details affect reproducibility. Analysts note that a reported purity figure does not by itself describe biological activity.

Bremelanotide Background and Receptor Pharmacology

PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.

Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.

Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.

Notes from published material

=== Separation based on hydrophobicity (hydrophobic interaction chromatography) === HIC media is amphiphilic, with both hydrophobic and hydrophilic regions, allowing for the separation of proteins based on their surface hydrophobicity. Target proteins and their product aggregate species tend to have different hydrophobic properties and removing them via HIC further purifies the protein of interest. Additionally, the environment used typically employs less harsh denaturing conditions than other chromatography techniques, thus helping to preserve the protein of interest in its native and functional state. In pure water, the interactions between the resin and the hydrophobic regions of protein would be very weak, but this interaction is enhanced by applying a protein sample to HIC resin in a high ionic strength buffer. The ionic strength of the buffer is then reduced to elute proteins in order of decreasing hydrophobicity.

== Function == Within blood, thrombins cleave fibrinogens to fibrins during coagulation and a fibrin-based blood clot forms. Factor XIII is a transglutaminase that circulates in human blood as a heterotetramer of two A and two B subunits. Factor XIII binds to the clot via their B units. In the presence of fibrins, thrombin efficiently cleaves the R37–G38 peptide bond of each A unit within a XIII tetramer. A units release their N-terminal activation peptides. Both of the non-covalently bound B units are now able to dissociate from the tetramer with the help of calcium ions (Ca2+) in the blood; these ions also activate the remaining dimer of two A units via a conformational change. Factor XIIIa (dimer of two active A units) crosslinks fibrins within the clot by forming isopeptide bonds between various glutamines and lysines of the fibrins. These bonds make the clot physically more durable and protect it from premature enzymatic degradation (fibrinolysis). In humans, plasmin, antithrombin and TFPI are the most relevant proteolytic inhibitors of the active factor XIIIa. α2-macroglobulin is a significant non-proteolytic inhibitor.

FeCl3 + BBr3 (excess) → FeBr3 + BCl3 When a lower bromide is wanted, either a higher halide may be reduced using hydrogen or a metal as a reducing agent, or thermal decomposition or disproportionation may be used, as follows:

Sources: en.wikipedia.org

Further detail

=== Neurodegenerative diseases === AEP is activated during brain ischemia or brain acidosis and epilepsia seizure. It digests SET protein, which is an inhibitor of DNase, leading to DNA damage and causing damage of the brain. Increased activity of AEP in brain is also observed in patients with Alzheimer's disease and Parkinson's disease (PD). AEP cleaves tau protein and amyloid precursor protein. In patients with PD, alpha synuclein is cut by AEP into toxic chunks., which are hypothesized to possibly play a role in the initiation or pathogenesis of PD

is the fourth-order tensor representing the constant of proportionality, called the viscosity or elasticity tensor, and : is the double-dot product. the fluid is assumed to be isotropic, as with gases and simple liquids, and consequently

In contrast, the Assad regime put more money into funding the captagon industry, transforming the country into a narcostate dependent on drug exports for revenue. Corruption ran rife after 2018, and conscripts within the SAA grew demoralized as key allies in the early years of the war such as Iran, Russia, and Hezbollah were involved in wars elsewhere.

Sources: en.wikipedia.org

Background from the literature

=== Depression === Levodopa has been reported to be inconsistently effective as an antidepressant in the treatment of depressive disorders. However, it was found to enhance psychomotor activation in people with depression.

Improvements in shipping technology allowed traders to sail around Jutland and into the Baltic Sea directly, and Danish warships collected the Sound Toll from these mainly Dutch merchants, in exchange for protection. Nordic rulers before the mid-seventeenth century welcomed the Dutch merchants for their efficient shipping services and inflow of investments which boosted industrial development. According to economic historian Angus Maddison, Denmark was the sixth-most prosperous country in the world around 1600. The population size relative to arable agricultural land was small so that the farmers were relatively affluent, and Denmark was geographically close to the most dynamic and economically leading European areas since the 16th century: the Netherlands, the northern parts of Germany, and Britain. Still, 80 to 85% of the population lived in small villages on a subsistence level. Mercantilism was the leading economic doctrine during the 17th and 18th century in Denmark, leading to the establishment of monopolies like Asiatisk Kompagni, development of physical and financial infrastructure like the first Danish bank Kurantbanken in 1736 and the first "kreditforening" (a kind of building society) in 1797, and the acquisition of some minor Danish colonies like Tranquebar. At the end of the 18th century major agricultural reforms took place that entailed decisive structural changes. However, the Napoleonic Wars caused Copenhagen to lose its status as an international center of finance and trade.

==== Silver mirror reaction ==== The silver mirror reaction involves the conversion of silver nitrate to Ag(NH3)OH. Ag(NH3)OH is subsequently reduced into colloidal silver using an aldehyde containing molecule such as a sugar. The silver mirror reaction is as follows:

7 June Rishi Sunak is criticised for leaving the D-day commemorations early to return to the UK to work on the election campaign. He says: "On reflection, it was a mistake not to stay in France longer – and I apologise." Data produced by Zoopla indicates that rents for new properties rose by 6.6% in the year to April 2024, but that this was the slowest rise in two and a half years. 9 June – Restrictions on carrying more than 100ml of liquid in hand luggage are temporarily reintroduced at some regional airports in order to "enable further improvements to be made" to new checkpoint systems. Those affected are Newcastle, Leeds Bradford, London City, Aberdeen, Southend and Teesside. 10 June – Twenty buildings across the UK are vandalised as part of a co-ordinated attack by Palestine Action, a pro-Palestine group. 11 June A High Court judge rules that convicted sex offender Gary Glitter must pay more than £500,000 to a victim he abused when she was 12 years old. A 28-year-old man is arrested on suspicion of public order offences after objects are thrown at Nigel Farage during a campaign tour in Barnsley. Rishi Sunak unveils the Conservative Party's general election manifesto, which includes a further cut in National Insurance, a halving of immigration, and several new housing policies. Former UN secretary general Ban Ki-moon is awarded the inaugural King Charles III Harmony Award during a ceremony held at St James's Palace. Two animal rights protestors vandalise a portrait of Charles III at London's Philip Mould Gallery by covering it with posters.

Sources: en.wikipedia.org

Frequently asked questions

What does the code PT-141 designate?

PT-141 was the internal development code assigned to bremelanotide during preclinical research. Reference sources sometimes index the peptide under the code rather than the generic name. The two terms describe the same molecule.

Is bremelanotide the same compound as melanotan II?

They are related but distinct cyclic peptides. Melanotan II is an earlier and less selective melanocortin analog. Bremelanotide was developed later with a narrower receptor profile and a defined clinical application.

How is the reviewed product administered?

The reviewed product is given by subcutaneous injection using a single-use autoinjector. Administration occurs under prescription supervision. The device delivers one fixed amount per use rather than a measured or adjustable quantity.

What does the evidence show about average effect size?

Trial results generally show a small to moderate average improvement in desire scores relative to placebo. The distribution of responses is wide, and some participants show little measurable change. Group averages should not be read as a prediction for any single person.

Network